Context Therapeutics Reports 22% Response Rate in Cancer Trial

Context Therapeutics

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) reported a 22% confirmed response rate in a small Phase 1 trial of its experimental ovarian cancer treatment, CTIM-76, as the Philadelphia-based biotechnology company prepares to expand testing in 2027 with $34.4 million in cash to fund continued development.

The results, based on nine evaluable patients with platinum-resistant ovarian cancer receiving biologically active weekly doses, showed a 56% disease control rate and median progression-free survival of 5.6 months, according to the company’s third-quarter financial and clinical update.

Two patients achieved confirmed partial responses, while three had stable disease. The patients had undergone extensive prior treatment, with a median of six previous lines of therapy among the broader group receiving biologically active doses.

The findings provide preliminary evidence of antitumor activity for CTIM-76, an investigational bispecific antibody designed to direct T cells toward cancer cells expressing Claudin 6, or CLDN6.

Context is evaluating the treatment in patients with CLDN6-positive ovarian, testicular and endometrial cancers. The U.S. Food and Drug Administration previously granted CTIM-76 Fast Track designation for patients with platinum-resistant ovarian cancer who have exhausted standard treatment options.

As of October 30, 27 patients had received CTIM-76 across the Phase 1 dose-escalation program, including 20 with ovarian cancer, four with testicular cancer and three with endometrial cancer.

READ:  Cencora Forecasts Up to 10% Earnings Growth After Record Year

Among 15 patients with platinum-resistant ovarian cancer treated at biologically active doses, 80% had previously received an antibody-drug conjugate, including five patients who had received at least two such treatments.

Tumor reductions were observed at multiple metastatic sites. All seven measurable liver lesions tracked in four patients decreased in size, with a median reduction of 58%, including two lesions that disappeared completely.

Safety findings remain an important consideration as the company evaluates higher doses and less frequent administration.

Cytokine release syndrome occurred in five of the 27 treated patients, or 18.5%, with all cases classified as Grade 1 or 2.

Severe treatment-emergent adverse events, classified as Grade 3 or higher, occurred in 22 patients, representing 81.5% of the overall study population.

The most frequently reported severe laboratory abnormalities included elevated liver enzymes, increased lipase and anemia. Liver enzyme elevations were dose-related and occurred most often at the highest weekly dose of 560 micrograms.

Context reported that these elevations generally developed early, were asymptomatic and resolved during continued treatment.

The company has completed the dose-limiting toxicity assessment for six patients receiving 280 micrograms every three weeks and has begun escalating the dose to 420 micrograms. Six additional patients are being enrolled at the 280-microgram level.

READ:  Enviri Sets November 19 Investor Presentation in Dallas

Early pharmacodynamic findings showed dose-dependent increases in immune signaling proteins and T-cell activation, with stronger responses observed among patients experiencing tumor reductions.

“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy,” said Martin Lehr, Context’s chief executive officer.

The company plans to begin Phase 1b dose expansion in the first quarter of 2027, targeting patients who have received no more than five prior lines of therapy.

That strategy is intended to evaluate whether treating patients earlier in their disease course, combined with dosing every three weeks, can improve clinical outcomes and tolerability.

Initial efficacy results from the three-week dosing schedule are expected in the second quarter of 2027.

Context is also advancing CT-202, a separate investigational bispecific antibody targeting Nectin-4 and CD3 for patients with urothelial, colorectal and triple-negative breast cancers.

The first patient entered the Phase 1 study in September, and six clinical sites are operating in Australia. Context expects to file a U.S. investigational new drug application by the end of 2026, with initial clinical data anticipated in the second half of 2027.

READ:  Mid Penn Bank Gives $100,000 to Penn Medicine Cancer Center

Financially, Context reported a third-quarter net loss of $7.6 million, narrowing from $9.7 million a year earlier.

Research and development expenses declined to $5.7 million from $8.7 million, primarily reflecting a $3.9 million reduction in CT-202 spending on contract manufacturing and preclinical activities.

Higher spending on CTIM-76, CT-95 and personnel partially offset those savings.

General and administrative expenses increased to $2.2 million from $1.9 million, driven by higher personnel costs and stock-based compensation.

Other income declined to $300,000 from $900,000 as interest earnings decreased alongside the company’s cash balance.

Context held $34.4 million in cash and cash equivalents as of September 30, down from $66 million at the end of 2025.

The company expects its remaining cash to support operations into early fourth-quarter 2027, covering the planned Phase 1b expansion and upcoming clinical readouts for its lead cancer treatment programs.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.